# A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

> **NCT00785538** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12

## Key facts

- **NCT ID:** NCT00785538
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785538, "A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00785538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*